The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Highlights from the BSH amyloidosis session
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London, London, UK, gives a brief overview of a session held at BSH 2022, which focused on the diagnosis, complications, and management of amyloidosis. Dr Wechalekar also highlights the excitement surrounding the use of daratumumab with bortezomib, cyclophosphamide and dexamethasone for the future treatment of light chain (AL) amyloidosis. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Honorarium/Advisory boards/Travel support: Alexion, Janssen, Attralus, GSK, Takeda
